Login to Your Account



Bayer and Crispr Therapeutics ink alliance targeting genetic diseases

By Peter Winter
BioWorld Insight Editor

Monday, December 21, 2015

It has been a hectic year for Crispr Therapeutics AG, which is ending with a flourish following the announcement that Bayer AG is investing a total of $335 million to establish a long-term alliance that will leverage promising CRISPR-Cas9 gene-editing technology.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription